GMDA Overview

Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The following are the Company's clinical pipeline products: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.

Wall Street analysts forecast GMDA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMDA is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Gamida Cell Ltd revenue for the last quarter amounts to 890.00K USD, decreased % YoY.

Gamida Cell Ltd. EPS for the last quarter amounts to -0.13 USD, decreased -51.85 % YoY.

Gamida Cell Ltd (GMDA) has 145 emplpoyees as of January 30 2026.

Today GMDA has the market capitalization of 5.00M USD.